[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021013218A - Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. - Google Patents

Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.

Info

Publication number
MX2021013218A
MX2021013218A MX2021013218A MX2021013218A MX2021013218A MX 2021013218 A MX2021013218 A MX 2021013218A MX 2021013218 A MX2021013218 A MX 2021013218A MX 2021013218 A MX2021013218 A MX 2021013218A MX 2021013218 A MX2021013218 A MX 2021013218A
Authority
MX
Mexico
Prior art keywords
cancer
compositions
treatment
methods
tet2
Prior art date
Application number
MX2021013218A
Other languages
English (en)
Inventor
Alex Franzusoff
Barbara Sennino
Stefanie Mandl-Cashman
Kyle Jacoby
Michael M Dubreuil
John Gagnon
Original Assignee
Pact Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pact Pharma Inc filed Critical Pact Pharma Inc
Publication of MX2021013218A publication Critical patent/MX2021013218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Composiciones y métodos para el tratamiento del cáncer usando una terapia celular basada en neoTCR con una inactivación de la expresión del gen TET2.
MX2021013218A 2019-05-01 2020-04-30 Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. MX2021013218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841748P 2019-05-01 2019-05-01
US201962841753P 2019-05-01 2019-05-01
PCT/US2020/030704 WO2020223478A1 (en) 2019-05-01 2020-04-30 Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy

Publications (1)

Publication Number Publication Date
MX2021013218A true MX2021013218A (es) 2021-12-10

Family

ID=73029470

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021013225A MX2021013225A (es) 2019-05-01 2020-04-30 Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8.
MX2021013218A MX2021013218A (es) 2019-05-01 2020-04-30 Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021013225A MX2021013225A (es) 2019-05-01 2020-04-30 Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8.

Country Status (11)

Country Link
US (3) US20210085720A1 (es)
EP (2) EP3962938A4 (es)
JP (2) JP2022531231A (es)
KR (2) KR20220005050A (es)
CN (1) CN113748127A (es)
AU (2) AU2020264484A1 (es)
CA (2) CA3136740A1 (es)
IL (2) IL287639A (es)
MX (2) MX2021013225A (es)
SG (2) SG11202111532SA (es)
WO (3) WO2020223537A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856769A4 (en) * 2018-09-28 2022-08-17 Memorial Sloan Kettering Cancer Center IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
EP4025689A1 (en) * 2019-09-06 2022-07-13 CRISPR Therapeutics AG Genetically engineered t cells having improved persistence in culture
AU2021261011A1 (en) * 2020-04-24 2022-11-10 Pact Pharma, Inc. Methods of determining gene editing efficiencies in cells
WO2022109277A1 (en) * 2020-11-20 2022-05-27 Pact Pharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
EP4259651A2 (en) * 2020-12-14 2023-10-18 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2022140361A1 (en) * 2020-12-22 2022-06-30 Ludwig Institute For Cancer Research Ltd Genetically engineered lymphocytes for adoptive cell therapy
WO2022177970A1 (en) * 2021-02-18 2022-08-25 University Of Florida Research Foundation, Incorporated Enhancing metabolic fitness of t cells to treat cancer
JP2024510900A (ja) 2021-02-25 2024-03-12 ライエル・イミュノファーマ・インコーポレイテッド Ａｐ－１転写因子をコードするコドン最適化ヌクレオチド配列
JP2024510898A (ja) 2021-02-25 2024-03-12 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１を標的とするキメラ抗原受容体
CN117836625A (zh) * 2021-06-11 2024-04-05 Pact制药公司 细胞产品的评估方法
AU2022376953A1 (en) 2021-10-28 2024-05-02 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2023077032A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
CN114373511B (zh) * 2022-03-15 2022-08-30 南方医科大学南方医院 基于5hmC分子标志物检测的肠癌模型及肠癌模型构建方法
WO2023212507A1 (en) * 2022-04-26 2023-11-02 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024064606A2 (en) * 2022-09-19 2024-03-28 Emendobio Inc. Biallelic knockout of ctla4
WO2024064607A2 (en) * 2022-09-19 2024-03-28 Emendobio Inc. Biallelic knockout of tet2
WO2024064637A2 (en) * 2022-09-19 2024-03-28 Emendobio Inc. Biallelic knockout of faslg
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN116179495A (zh) * 2022-11-28 2023-05-30 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US20020127594A1 (en) * 2000-06-22 2002-09-12 Gearing David P. Don-1 gene and polypeptides and uses therefor
US6355412B1 (en) * 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
EP3626261A1 (en) * 2013-11-21 2020-03-25 UCL Business Ltd Cell
CN108633287A (zh) * 2015-09-17 2018-10-09 诺华股份有限公司 功效增强的car t细胞治疗
MX2018007519A (es) * 2015-12-18 2019-09-04 Sangamo Therapeutics Inc Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
EP3440101B1 (en) * 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
EP3516044A4 (en) * 2016-09-23 2020-03-11 Fred Hutchinson Cancer Research Center SPECIFIC TCRs OF THE MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF
KR20190100200A (ko) * 2016-11-22 2019-08-28 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CA3055983A1 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof
EP3601561A2 (en) * 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
US11512287B2 (en) * 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
JP2020530274A (ja) * 2017-06-30 2020-10-22 アカデミス・ジーケンハイス・ライデン・ハー・オー・デー・エヌ・エルユーエムセーＡｃａｄｅｍｉｓｃｈ Ｚｉｅｋｅｎｈｕｉｓ Ｌｅｉｄｅｎ Ｈ．Ｏ．Ｄ．Ｎ． Ｌｕｍｃ 造血器腫瘍の処置
US20210130845A1 (en) * 2017-09-08 2021-05-06 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
CA3081320A1 (en) * 2017-10-30 2019-05-09 Pact Pharma, Inc. Primary cell gene editing
US20200338128A1 (en) * 2018-01-05 2020-10-29 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
WO2019195310A1 (en) 2018-04-02 2019-10-10 Pact Pharma, Inc. Peptide-mhc compacts
US20210317184A1 (en) * 2018-09-05 2021-10-14 GlaxoSmithKline Intellectual Property Devolopment Limited T cell modification
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN113784976A (zh) 2019-02-12 2021-12-10 派克特制药公司 用于鉴定抗原特异性t细胞的组合物和方法
BR112021023782A2 (pt) * 2019-05-27 2022-01-11 Immatics Us Inc Vetores, métodos de preparação de células t para imunoterapia, populações de células t expandidas e métodos para tratar de um paciente com câncer e para elicitar uma resposta imune

Also Published As

Publication number Publication date
SG11202111532SA (en) 2021-11-29
SG11202111865UA (en) 2021-11-29
JP2022530653A (ja) 2022-06-30
CA3151385A1 (en) 2020-11-05
CA3136740A1 (en) 2020-11-05
WO2020223537A1 (en) 2020-11-05
WO2020223625A1 (en) 2020-11-05
AU2020264484A1 (en) 2021-11-04
EP3962938A1 (en) 2022-03-09
KR20220004703A (ko) 2022-01-11
WO2020223478A1 (en) 2020-11-05
MX2021013225A (es) 2022-01-06
US20210085720A1 (en) 2021-03-25
JP2022531231A (ja) 2022-07-06
EP3953379A1 (en) 2022-02-16
AU2020266579A1 (en) 2021-11-25
US20220193139A1 (en) 2022-06-23
WO2020223537A8 (en) 2021-11-11
US20210085721A1 (en) 2021-03-25
EP3962938A4 (en) 2023-07-05
CN113748127A (zh) 2021-12-03
US11304978B2 (en) 2022-04-19
EP3953379A4 (en) 2023-05-31
KR20220005050A (ko) 2022-01-12
IL287639A (en) 2021-12-01
IL287643A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
WO2018067512A8 (en) SPIROCYCLIC COMPOUNDS
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
WO2018136617A3 (en) Bacteria for treating cancer
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EP3880215A4 (en) COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2017012553A (es) Compuestos espirociclicos.
MX2021001062A (es) Terapia genica no disruptiva para el tratamiento de acidemia metilmalonica (mma).
MX2020011470A (es) Metodos de terapia genica.
ZA202103975B (en) Methods of treating disease with magl inhibitors
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2017014436A (es) Compuestos biciclicos.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.